Leap Therapeutics Inc
NASDAQ:LPTX

Watchlist Manager
Leap Therapeutics Inc Logo
Leap Therapeutics Inc
NASDAQ:LPTX
Watchlist
Price: 0.3234 USD 3.62% Market Closed
Market Cap: 13.4m USD

EV/EBIT
Enterprise Value to EBIT

0.3
Current
0.1
Median
5.3
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
0.3
=
Enterprise Value
-19.3m USD
/
EBIT
-71.1m USD
EBIT Growth EV/EBIT to Growth
US
Leap Therapeutics Inc
NASDAQ:LPTX
Average EV/EBIT: 16.3
0.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 879.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.6
28%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.2
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
15.1
12%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.7 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21
17%
1.2
AU
CSL Ltd
ASX:CSL
23.8
14%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.4
10%
1.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -302.4 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.6 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
0.4
2-Years Forward
EV/EBIT
0.5
3-Years Forward
EV/EBIT
0.4